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ABSTRACT
Purpose: We hypothesized that bortezomib, an agent that suppresses HIF-1α 
transcriptional activity, when combined with bevacizumab, would obviate the  
HIF-1α resistance pathway. The objectives of this phase I trial were to assess safety 
and biological activity of this combination.
Experimental Design: Patients with advanced, refractory malignancies were 
eligible. Patients received bevacizumab and bortezomib (3-week cycle) with 
dose expansions permitted if responses were seen and for assessing correlates. 
Pharmacodynamic assessment included plasma VEGF, VEGFR2, 20S proteasome 
inhibition, dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), and 
HIF-1α tumor expression.
Results: Ninety-one patients were treated (median=6 prior treatments). The 
FDA-approved doses of both drugs were safely reached, and the recommended 
phase 2 dose (RP2D) is bevacizumab 15 mg/kg with bortezomib 1.3 mg/m2. Four 
patients attained partial response (PR) and seven patients achieved stable disease 
(SD) ≥6 months (Total SD≥6 months/PR=11 (12%)). The most common drug-related 
toxicities included thrombocytopenia (23%) and fatigue (19%). DCE-MRI analysis 
demonstrated no dose-dependent decreases in Ktrans although analysis was limited 
by small sample size (N=12).
Conclusion: Combination bevacizumab and bortezomib is well-tolerated and 
has demonstrated clinical activity in patients with previously treated advanced 
malignancy. Pharmacodynamic assessment suggests that inhibition of angiogenic 
activity was achieved.
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INTRODUCTION
Angiogenesis, which has a fundamental role in 
tumor growth and metastasis [1-3], is important for 
supplying a growing tumor with oxygen, nutrients, 
growth factors, hormones, proteolytic enzymes, and 
hemolytic factors, and is a critical step in the pathogenesis 
of metastasis [2-4]. Increased tumor vascularization and 
tumor expression of pro-angiogenic factors has been 
associated with advanced tumor stage and poor prognosis 
[3]. The vascular endothelial growth factor (VEGF) family 
of proteins and receptors play a pivotal role in tumor 
angiogenesis and in the pathogenesis of a wide range of 
human cancers [5].
One mechanism of tumor resistance to anti-
angiogenic therapy is upregulation of the transcription 
factor hypoxia-inducible factor 1α (HIF-1α), which 
mediates adaptive responses to hypoxic conditions 
commonly found in solid tumors [3, 6-14]. HIF-1α 
promotes expression of various genes that encode 
proteins involved in inflammatory reactions involved in 
cancer [15]. HIF-1α overexpression has been identified in 
a number of tumor types, including pancreatic, head and 
neck, breast, renal, ovarian, bladder, brain, colorectal, 
and prostate cancers, and overexpression correlates with 
increased angiogenesis and metastasis [15, 16]. Thus, 
HIF-1α inhibition in combination with anti-angiogenic 
therapy is a promising strategy for targeting tumor 
resistance [11, 17-20].
Anti-angiogenic agents that target the VEGF 
pathway have demonstrated clinical benefit for a 
variety of malignancies, including colorectal, lung, 
glioblastoma, ovarian, and renal cell cancer [3, 10, 21-
25]. Bevacizumab is a monoclonal antibody to VEGF 
that is FDA approved for the treatment of renal cell 
carcinoma, colorectal cancer, non-small cell lung cancer, 
and glioblastoma.
The proteasome is a large enzyme complex 
responsible for the regulation of proteins involved in 
various cell signaling pathways by degradation [26-28] 
and proteasome inhibition induces apoptosis by interfering 
with the regulation of signaling cascades implicated 
in cancer, such as the nuclear factor NF- κB [27, 29]. 
Bortezomib, a boronic acid bipeptide, is a specific and 
reversible inhibitor of the chymotrypsin-like activity of 
the 26S proteasome [30, 31]. While bortezomib exhibits 
pro-apoptotic, anti-angiogenic, and anti-proliferative 
activity, it has also demonstrated the ability to inhibit 
transcriptional activity of HIF-1α [27, 28, 30-33]. This 
appears to be a class effect as the proteasome inhibitors 
bortezomib and NPI-0052 have been shown in vitro 
to inhibit tumor angiogenesis as a result of decreased 
VEGF expression via downregulation of HIF-1α [33, 34]. 
Bortezomib is FDA approved for the treatment of multiple 
myeloma and mantle cell lymphoma. In phase I and II 
clinical trials, partial responses (PR) have been achieved 
in various solid tumors, including metastatic or recurrent 
renal cell carcinoma, non-small cell lung carcinoma, 
ovarian adenocarcinoma, pancreatic adenocarcinoma, and 
sarcoma [27, 31].
We performed a phase I trial administering 
sequential bevacizumab and bortezomib based on our 
hypothesis that this combination will obviate the HIF-1α 
pathway as a mechanism of resistance to bevacizumab. 
The primary objective of this study was to determine 
the maximum tolerated dose and dose-limiting toxicities 
of the combination treatment of bevacizumab with 
bortezomib. The secondary objectives were to establish a 
preliminary descriptive assessment of anti-tumor 
efficacy and  anti-angiogenesis correlates with the drug 
combination.
RESULTS
Patient characteristics
Ninety-one patients were enrolled (median 52.5 years 
old, range 27-78). The median number of prior systemic 
treatments was six. The majority of patients had an ECOG 
performance status of 1. The most common tumor types 
enrolled were RCC, breast cancer, rectal carcinoma, 
nasopharyngeal, neuroendocrine carcinoma, and prostate 
cancer (Table 1).
Toxicity and recommended dose
All patients were evaluated for toxicity (Table 2). 
The highest dose level, dose level 9, with doses of 
bevacizumab at 15mg/kg and bortezomib at 1.3mg/
m2, was reached without identification of an MTD and 
further dose escalation was not performed above the 
FDA-approved doses. Only one DLT was observed, 
which was grade 4 acute renal failure on Day 19 in a 
patient on dose level 9.
All dose levels were tested and shown to be safe. 
Overall, the most common drug-related toxicities grade 2 
or higher included thrombocytopenia (23%), fatigue 
(19%), nausea/vomiting (12%), diarrhea (12%), arthralgia/
myalgia (10%), anorexia (9%), anemia (9%), neutropenia 
(7%), and hypertension (6%). Thirty-three patients (36%) 
experienced no drug-related toxicity higher than grade 1 
and 66 patients (73%) had no drug-related toxicity higher 
than grade 2.
Adverse events that required a dose reduction 
occurred in 10 patients (11%). The causes of dose 
reduction were thrombocytopenia (n=5) and neuropathy 
(n=5). Four patients died while on treatment (two from 
sepsis, one from acute myocardial infarction likely 
related to sepsis, one from carotid hemorrhage, and 
one from suspected pulmonary embolism), but these 
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Table 1 Patient characteristics
Characteristic Total
Number of patients 91
Median age 52.5 yrs (Range 27-78)
Sex
 Male 49 (54%)
 Female 42 (46%)
ECOG PS
 0 7 (8%)
 1 74 (81%)
 2 10 (11%)
Prior treatment
 Surgery 70 (77%)
 Radiation 57 (63%)
 Chemotherapy 91 (100%)
 Phase I trial 34 (37%)
 Bevacizumab only 26 (29%)
 Bortezomib only 3 (3%)
 Bevacizumab and Bortezomib 1 (1%)
Median number of prior systemic 
treatments
5.5 (Range 0-11)
Median number of prior Phase I 
treatments
3 (Range 0-6)
Diagnosis
 Renal Cell Carcinoma 21 (23%)
 Breast 11 (12%)
 Colorectal Carcinoma 11 (12%)
 Nasopharyngeal 6 (7%)
 Gastric/esophageal 5 (5%)
 Neuroendocrine 5 (5%)
 Prostate 5 (5%)
 Pancreatic 3 (3%)
 Melanoma 3 (3%)
 Ovarian/fallopian tube 3 (3%)
 Leiomyosarcoma 2 (2%)
 Hepatocellular 2 (2%)
 Cervical 2 (2%)
 Urothelial 2 (2%)
 Other* 10 (11%)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, 
performance status; GE, gastroesophageal
*Other tumor types include one of each of the following: adenoid 
cystic carcinoma, adrenocortical carcinoma, mucinoid carcinoma of 
the appendix, B-cell lymphoma, cholangiocarcinoma, granular cell 
carcinoma, paraganglioma, parotid carcinoma, piriform sinus carcinoma, 
small cell lung carcinoma
events were not treatment related. Seven patients were 
withdrawn due to toxicity, including neuropathy (n=1), 
neuropathy and gastrointestinal bleed (n=1), pulmonary 
embolism (n=1), hyponatremia (n=1), renal failure 
(n=1), renal failure and altered mental status (n=1), 
and diarrhea, nausea, anorexia and body aches (n=1). 
Because of adequate safety observed, the recommended 
phase 2 dose was determined to be level 9, which 
includes the recommended FDA-approved full dose of 
each medication, bevacizumab 15mg/kg and bortezomib 
1.3mg/m2.
Antitumor activity
Eleven out of 91 patients (12%) received more 
than 6 months of treatment (Table 3). Among the 91 
treated patients, four patients achieved partial response, 
39 patients achieved stable disease (SD), 43 patients 
had progressive disease (PD), and five patients were 
inevaluable (Figure 1a). The partial responses included 
three patients with renal cell carcinoma (−88%, −45%, 
−30%) (Figure 1b) and one patient with nasopharyngeal 
carcinoma (−38%) (Figure 1c).
The median number of months of treatment 
received was 2 (range 0-14). Sixty-eight out of 91 patients 
were measurable per RECIST. Among the remaining 
23 patients, 18 were evaluable but not measurable 
and five were not evaluable because treatment was 
discontinued before the first restaging evaluation 
(one for toxicity (carotid hemorrhage)), and three 
withdrew consent (one due to side effects and desire 
to pursue therapy closer to home, one so other therapy 
could be pursued closer to home, and one because 
the patient felt the dose of bevacizumab was too low 
since higher doses were received on previous therapy).
The median time to treatment failure (TTF) was 
2 months (range 0-14), and the median overall survival 
(OS) was 7 months (range 0-43). 
Prior bevacizumab and/or bortezomib
Out of 91 patients treated on study, thirty received 
prior bevacizumab or bortezomib (33%, Table 1). Twenty-
six patients received prior bevacizumab only, three patients 
received prior bortezomib only, and 1 patient received 
prior bortezomib and bevacizumab, but not concurrently. 
The median number of months of prior bevacizumab/
bortezomib therapy was 4.5. No statistically significant 
correlation was observed in response or time on treatment 
when comparing patients who received prior bevacizumab 
or bortezomib with patients who had not received prior 
bevacizumab or bortezomib (30 and 61 patients, p=0.43, 
p=0.73, respectively). Of note, 4 of the 11 patients 
with SD≥6 months or PR received prior bevacizumab 
or bortezomib (renal cell carcinoma, nasopharyngeal 
carcinoma, leiomyosarcoma, hepatocellular carcinoma). 
The renal cell carcinoma patient with the best response 
on study (88% decrease in tumor size) had previously 
received bevacizumab.
Correlatives
VEGF and VEGFR2
Plasma VEGF and VEGFR2 levels were tested 
in 55 patient samples with time points at pre-dose, 24 
hours post-dose, and week three. While samples were 
analyzed from some patients at all three time points, not 
all time points were available for each patient. Of the 55 
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Table 2  Toxicities
Toxicity By Dose Level DL 1
(N=7)
DL 2 
(N=6)
DL 3
(N=6)
DL 4
(N=6)
DL 5
(N=6)
DL 6
(N=6)
DL 7 
(N=6)
DL 8
(N=6)
DL 9
(N=37)
Total 
(N=91)
Bevacizumab mg/kg IV 2.5 2.5 5 5 7.5 7.5 10 12.5 15
Bortezomib mg/m2 IV 0.7D1, 8
0.7
D1, 4, 8, 11 0.7 1.0 1.0 1.3 1.3 1.3 1.3
Thrombocytopenia
 Grade 2 0 2 (2%) 0 0 0 1 (1%) 3 (3%) 1 (1%) 3 (3%) 10 (11%)
 Grade 3 0 0 1 (1%) 0 1 (1%) 1 (1%) 1 (1%) 0 6 (7%) 10 (11%)
 Grade 4 0 0 0 0 0 0 1 (1%) 0 0 1 (1%)
Fatigue
 Grade 2 1 (1%) 1 (1%) 0 2 (2%) 0 1 (1%) 2 (2%) 1 (1%) 7 (8%) 15 (16%)
 Grade 3 0 0 0 0 0 0 0 0 2 (2%) 2 (2%)
Nausea/Vomiting
 Grade 2 0 0 0 0 0 1 (1%) 2 (2%) 0 7 (8%) 10 (11%)
 Grade 3 0 0 0 0 0 0 0 0 1 (1%) 1 (1%)
Diarrhea
 Grade 2 0 0 0 0 0 0 4 (4%) 0 5 (5%) 9 (10%)
 Grade 3 0 0 0 0 0 0 0 0 2 (2%) 2 (2%)
Arthalgia/Myalgia
 Grade 2 0 0 0 1 (1%) 2 (2%) 1 (1%) 1 (1%) 1 (1%) 3 (3%) 9 (10%)
Neuropathy
 Grade 2 1 (1%) 0 0 0 0 0 0 0 6 (7%) 7 (8%)
 Grade 3 0 0 0 0 0 0 2 (2%) 0 0 2 (2%)
Anorexia
 Grade 2 0 1 (1%) 0 0 0 0 1 (1%) 0 6 (7%) 8 (9%)
Anemia
 Grade 2 0 1 (1%) 1 (1%) 1 (1%) 2 (2%) 1 (1%) 0 0 1 (1%) 7 (8%)
 Grade 3 0 0 1 (1%) 0 0 0 0 0 0 1 (1%)
Neutropenia
 Grade 2 0 0 0 1 (1%) 0 0 1 (1%) 0 0 2 (2%)
 Grade 3 0 0 0 0 0 1 (1%) 0 0 2 (2%) 3 (3%)
 Grade 4 0 0 0 0 0 0 0 0 1 (1%) 1 (1%)
Hypertension
 Grade 2 0 0 0 0 0 0 1 (1%) 0 1 (1%) 2 (2%)
 Grade 3 0 0 0 0 0 0 0 3 (3%) 0 3 (3%)
*Grade 3, 4, and 5 events were not included in the table if there were 0 events with that grade.
**Table includes Grade 2 and greater adverse events (AEs) occurring at a frequency of ≥ 5% of participants who received treatment on study. AEs occurring at 
a rate lower than 5% included: elevated AST/ALT (DL1, Grade 2, n = 1; DL2, Grade 2, n = 1; DL5, Grade 2, n = 1; DL6, Grade 2, n = 1), constipation (DL8, 
Grade 2, n = 1; DL9, Grade 2, n = 2), proteinuria (DL1, Grade 3, n = 1; DL2, Grade 3, n = 1; DL9, Grade 2, n = 1), pulmonary embolism (DL2, Grade 4, 
n =1; DL4, Grade 4, n = 1; DL9, Grade 5, n = 1), hemoptysis (DL2, Grade 3, n = 1; DL7, Grade 2, n = 1), elevated bilirubin (DL6, Grade 2, n = 1), dyspnea 
(DL7, Grade 2, n = 1), GI bleed (DL2, Grade 3, n = 1), headache (DL9, Grade 2, n = 1), hematuria (DL2, Grade 2, n = 1), hypotension (DL9, Grade 2, n = 1), 
pancreatitis (DL8, Grade 2, n = 1), acute renal failure (DL9, Grade 4, n = 1).
patients analyzed, six experienced either SD≥6 months 
or PR.
Plasma VEGF levels increased in patients at 
24 hours post-dose with an average percent increase of 
251% (n=33, p=0.001 with Wilcoxon signed-rank test). 
Overall plasma VEGF levels significantly increased from 
baseline at the three week time point (n=26, average 
increase of 1214%, p<0.001 with Wilcoxon signed-rank 
test). No significant differences were observed between 
patients with SD≥6 months/PR and patients with PD 
or SD for less than 6 months when comparing baseline 
values (n=6 vs. n=47, average of 109.6pg/ml vs. 266.9pg/
ml, p=0.54 with Mann-Whitney test).
Plasma levels of VEGFR2 increased slightly 
overall from pre-dose to 24 hours post-dose in the 33 
patients who had blood samples available for both 
time points (average increase of 6.98%, p<0.001 
with paired t-test). Another small overall increase in 
plasma VEGFR2 was observed from pre-dose to Week 
3 (average increase of 10.19%, p=0.02 with paired 
t-test), although only 8 patients had samples at both 
time points. No significant differences were observed 
between patients with SD≥6 months/PR and PD/SD<6 
months when comparing baseline values (n=6 vs. n=47, 
average of 8010pg/ml vs. 7844pg/ml, p=0.83 with 
unpaired t-test).
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HIF-1α
Among the 14 patients who underwent tumor 
biopsies while on study, only five patients had adequate 
tissue from both the pre- and post-dose tumor biopsies. 
Characteristics of HIF-1α analysis in all biopsied tissue 
is displayed in Supplementary Table S1. Among the five 
patients with both pre- and post-dose tumor biopsies, 
four had positive HIF-1α staining at baseline. All four 
patients with positive HIF-1α at baseline demonstrated 
a decrease in HIF-1α staining in the post-dose biopsy, 
including three patients whose post-dose biopsy became 
completely negative for HIF-1α. The average percentage 
of cells staining for HIF-1α at baseline in these five 
patients was 68% (100%, 100%, 100%, 40%, and 0%, 
respectively) compared to 26% post-dose (40%, 0%, 0%, 
0%, and 90%, respectively) (Figure 3). The small number 
of patients precluded statistical correlation with response, 
but two of the four patients with a decrease of HIF-1α 
expression experienced a decrease in tumor size (19% 
and 15% decrease in prostate and fallopian tube cancers, 
respectively).
20S Proteasome activity
Inhibition of 20S proteasome activity was 
analyzed in plasma samples obtained from 31 patients. 
The figures can be viewed in Supplementary Figure 
S1. Three of the 31 patients experienced PR or SD≥6 
months. Overall, 20S proteasome activity significantly 
decreased within 1 and 4 hours after treatment (average 
decrease of 10.44%, p=0.014 and 18.81%, p=0.004, 
respectively, with Wilcoxon signed-rank test), but changed 
inconsistently after day 2/3 (average increase of 3.54%, 
p=0.925 with Wilcoxon signed-rank test). This trend 
was observed whether the samples were separated by 
dose level (dose levels of bortezomib at 0.7-1.0mg/m2 
(low) vs. 1.3mg/m2 (high)), response (SD≥6 months/PR 
vs. SD<6 months/PD), or toxicity (Grade 2 or greater 
thrombocytopenia, diarrhea, nausea, vomiting, and/or 
neuropathy vs. none/other). No significant differences 
in change in 20S proteasome activity were observed 
when comparing patients with SD≥6 months/PR against 
all others, when comparing patients with the described 
toxicities against all others and also stratified by dose, or 
when comparing low versus high dose levels. Some of 
these comparisons, such as those for SD≥6 months/PR 
against all others were limited by the small number of 
patients.
DCE-MRI
All patients were screened for eligibility for DCE-
MRI. The DCE-MRIs of 14 patients were analyzed. Among 
the 14 patients, 12 patients had DCE-MRI performed at all 
three time points (baseline, 24-48 hours, and end of cycle 
1), and two patients had DCE-MRI performed at only two 
time points (baseline and 24-48 hours).
DCE-MRI analysis demonstrated a trend in dose-
dependent decreases in Ktrans at 3 weeks (R=−0.83, 
p=0.0053) (Figure 2a). Patients who were treated at higher 
dose levels had a larger percentage decrease in Ktrans at 
3 weeks. Standard error was calculated for each time point 
and is included in Figure 2a. No statistically significant 
dose-dependent trend was observed at the 24-48 hour time 
point.
Among the 14 patients evaluated, four patients 
received more than four cycles of treatment. These four 
Table 3  Patients on study ≥ 6 months or with partial response
Best 
Response 
(%)
Treatment 
duration 
(months)
Tumor type Prior 
bevacizumab
Prior 
bortezomib
Brain 
mets
Dose 
Level
Hypertension 
grade
VEGF SNPs Maximum 
% change 
in VEGF
Maximum 
% change 
in VEGFR22578 1154 1498 634
−88% 14 RCC Y N N 9 None A/C G/A C/T C/G - -
−45% 8 RCC N N N 2 1 A/C G/A C/T C/G - -
−38% 5 NPC N Y N 9 None - - - - - -
−30% 6 RCC N N N 7 2 - - - - +342% +10%
−19% 9 Leiomyosarcoma Y N N 4 1 A/C AA TT C/G +259% +3.1%
−15% 8 Fallopian tube N N N 9 1 AA AA CC GG +826% +10.9%
−12% 7 NPC N N N 9 None - - - - - -
−8% 8 Neuroendocrine N N N 6 1 A/C G/A C/T C/G +1213% +11.6%
−2% 6 Hepatocellular Y Y N 5 1 A/C G/A C/T C/G +1566% -
−2% 7 RCC N N N 7 None A/C G/A C/T GG +255% +8.1%
3% 6 RCC N N Y 9 None - - - - - -
RCC = Renal Cell Carcinoma, NPC = Nasopharyngeal Carcinoma, “-” = Not available
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Figure 1: (a). 3D Waterfall plot showing best response and time on study in 86 evaluable patients. Five patients omitted from the 
figure were not evaluable because treatment was discontinued before the first restaging evaluation (one for toxicity (carotid hemorrhage)), and 
three withdrew consent (one due to side effects and desire to pursue therapy closer to home, one so other therapy could be pursued closer to home, 
and one because the patient felt the dose of bevacizumab was too low since higher doses were received on previous therapy). The x-axis represents 
each patient. The y-axis indicates percent change in tumor size by RECIST. Patients who experienced partial response are shown in green, patients 
with stable disease in yellow, and patients with progressive disease in red. Patients with early clinical progression or new lesions are indicated 
arbitrarily as +21% and are denoted with a star (*). The treatment duration (months) for each patient is depicted by the grey bars on the z-axis. Bars 
that are not to scale are denoted with double line “breaks”. (b). Treatment response of 64 y/o woman with metastatic renal cell carcinoma 
(RCC). Patient received 20 cycles of treatment (14 months) and achieved partial response (PR) (88% decrease in tumor size per RECIST). 
(c). Treatment response of 48 y/o man with metastatic nasopharyngeal carcinoma. Patient received 6 cycles of treatment (5 months) and 
achieved partial response (PR) (38% decrease in tumor size per RECIST).
Abbreviations: RECIST, response evaluation criteria in solid tumors
a.
b.
c.
Oncotarget10286www.impactjournals.com/oncotarget
patients did not demonstrate a statistically significant 
trend of greater decrease of Ktrans at either the 24-48 hour 
time point or the 3 week time point. At 24-48 hours, the 
decrease of Ktrans among patients who eventually received 
more than 4 cycles of treatment was 18.3% (standard 
error 21.2%), compared to 24.2% (standard error 48.0%) 
in the remainder of the patients. This trend of difference 
between the two groups was not statistically significant 
(p=0.24 with paired t-test). At 3 weeks, the decrease of 
Ktrans among patients who received more than 4 cycles of 
treatment was 14.4% (standard error 12.8%), compared to 
16.4% (standard error 9.2%) in the remainder of patients 
(p=0.79 with two-tailed paired t-test). A representation 
of DCE-MRI analysis of a patient with nasopharyngeal 
carcinoma is shown in Figure 2b.
VEGF selected genotypes analysis
Because of previous published evidence that 
polymorphisms of VEGF may correlate with the efficacy 
and toxicity of bevacizumab combination treatment, 
analyses of associations among selected VEGF genotypes 
and treatment outcomes were performed [35]. Schneider 
et al. previously demonstrated that VEGF-2578 AA and 
VEGF-1154A correlated with superior overall survival and 
VEGF-634 CC and VEGF-1498 TT associated with less 
grade 3/4 hypertension.
Patients (n=7) with VEGF-634 GG genotype 
compared to 9 patients with VEGF-634 GC and VEGF-
634 CC genotypes had longer median time to treatment 
failure (TTF) (1.8, 95% CI 0.5-3.1 vs. 0.7 months, 95% 
CI 0.1-1.3; p=0.045) and patients (n=6) with VEGF-634 
GC genotype compared to 10 patients with VEGF-634 
GG and VEGF-634 CC genotypes had shorter median 
TTF (0.7, 95% CI 0.2-1.2 vs. 1.3 months, 95% CI 0.1-2.5; 
p=0.042).
Patients (n=4) with VEGF-2578 AA genotype 
compared to 20 patients with VEGF-2578 AC and VEGF-
2578 CC genotypes had longer median overall survival 
(OS) (19.8 months, 95% CI 0.0-44.9 vs. 7.5 months, 95% 
CI 6.6-8.4; p=0.03). Also, 4 patients with VEGF-1498 
CC genotype compared to 14 patients with VEGF-1498 
CT and VEGF-1498 TT genotypes had longer median OS 
(21.8, 95% CI 0.0-46.9 vs. 7.5 months, 95% CI 4.2-10.8; 
p=0.019) and 11 patients with VEGF-1498 CT genotype 
compared to 7 patients with either VEGF-1498 CC or 
VEGF-1498 TT genotypes had shorter median OS (5.7 
months, 95% CI 2.4-9.0 vs.21.7 months, 95% CI 0.0-
44.3; p=0.023). Finally, 7 patients with VEGF-634 GG 
genotype compared to 9 patients with VEGF-634 GC and 
VEGF-634 CC genotypes had longer median OS (19.5, 
95% CI 0.0-46.4 vs. 4.2 months, 95% CI 1.6-6.8; p=0.029) 
and 6 patients with VEGF-634 GC genotype compared 
to 10 patients with VEGF-634 GG and VEGF-634 CC 
genotypes had shorter median OS (2.4, 95% CI 0.0-5.9 vs. 
12.9 months, 95% CI 0.0-29.2; p=0.008).
DISCUSSION
In this study, we report the results of a phase I 
dose-escalation trial of combination bevacizumab and 
bortezomib. The rationale for this combination from 
preclinical and clinical studies was based on the use of 
bortezomib to overcome resistance to anti-angiogenic 
therapy via blockade of HIF-1α upregulation [3, 7-14, 
19, 33]. The combination of drugs was well-tolerated. 
We successfully completed dose escalation to the highest 
specified dose level, i.e. the FDA-approved doses of both 
drugs (bevacizumab 15mg/kg and bortezomib 1.3mg/m2), 
without reaching a MTD. Therefore, the recommended 
phase 2 dose was determined to be the full FDA-approved 
doses for both drugs.
The safety profile of combination treatment with 
bevacizumab and bortezomib was successfully determined, 
with the caveat that the MTD was never reached in this 
study. Combination treatment with bevacizumab and 
bortezomib was well-tolerated, with 36% of patients 
who experienced no treatment-related toxicity greater 
than grade 1 and 72% of patients who experienced no 
treatment-related toxicity greater than grade 2. Treatment-
related grade 3 and 4 toxicities included thrombocytopenia, 
fatigue, nausea/vomiting, diarrhea, neuropathy, anemia, 
neutropenia, and hypertension, which are consistent with 
the known toxicity profiles of the drugs. There were no 
treatment-related deaths.
Five of 20 evaluable patients with advanced renal 
cell carcinoma (median=4 prior treatments) experienced 
SD≥6 months/PR on study (PR; N=3). The number of 
patients is small but the 25% SD≥6 months/PR rate was 
higher than would have been expected for treatment with 
either agent alone in heavily pretreated patients [24, 
36-38], suggesting that the combination may warrant 
further study in this histology. In phase II studies of renal 
cell carcinoma patients treated with bevacizumab in the 
first-line or second-line metastatic setting, response rates 
of 13% and 10%, respectively, were observed [24, 36]. 
In phase II studies of renal cell carcinoma patients treated 
with bortezomib in the second- or third-line setting, 
response rates of 5% and 11%, respectively, were observed 
[37, 38].
Two of six patients (33%) with nasopharyngeal 
carcinoma experienced SD≥6 months (N=1) or a PR 
(N=1) on study. No monotherapy studies of bevacizumab 
or bortezomib have evaluated activity in nasopharyngeal 
carcinoma, and there have been only limited combinations 
studies. In one previous study, 46 patients with stage 
IIB-IVB nasopharyngeal carcinoma were treated with 
bevacizumab in addition to standard chemoradiation. The 
two-year locoregional progression-free survival rate was 
84% compared to 90% in other chemoradiation studies 
[39]. In a phase I dose escalation study of bortezomib with 
gemcitabine and liposomal doxorubicin, 1 nasopharyngeal 
carcinoma patient out of 11 patients with advanced head 
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Figure 2: (a). Dose-dependent changes in the volume transfer constant (Ktrans) at 3 weeks (n=9) (stratified by bevacizumab 
dose) (R=−0.83, p=0.0053). (b). DCE-MRI analysis of nasopharyngeal carcinoma. On the parametric color map, areas with the 
highest tissue permeability (as assessed by Ktrans) are visualized as red, and areas with the lowest Ktrans values are visualized as blue
and neck cancers (9%) experienced a partial response 
[40]. A larger, biomarker-driven study may be warranted 
for combination bevacizumab and bortezomib in 
nasopharyngeal carcinoma to further explore the efficacy 
of this regimen.
HIF-1α has previously been shown to play an 
important role in renal cell carcinoma. In at least 60% 
of patients with sporadic clear-cell renal-cell carcinoma, 
the von Hippel–Lindau tumor-suppressor gene (VHL) is 
inactivated [41]. The VHL protein plays a critical role 
in the cellular pathway that couples changes in oxygen 
availability to gene expression through the regulation of 
HIF-1α. Under normal oxygen conditions, VHL binds 
HIF-1α, which leads to degradation of HIF-1α through 
various mechanisms. When VHL is not present, HIF-1α 
is not degraded. HIF-1α accumulates inappropriately 
in VHL-deficient cells during conditions of normal 
oxygen tension [41]. These cells overexpress HIF-
regulated genes, including genes encoding angiogenic 
factors [41]. The upregulation of HIF in cells deficient 
in VHL is critically important in the tumorigenesis of 
renal cell carcinoma [42]. Inactivation of HIF can inhibit 
tumorigenesis among VHL-deficient renal carcinoma 
cells in xenograft models [43]. VHL inactivation results 
in increased activity of HIF and increased VEGF 
expression [42]. Inhibition of VEGF with bevacizumab 
and inhibition of HIF-1α by bortezomib is a logical 
therapeutic combination for the treatment of RCC.
In our study, HIF-1 expression was evaluated 
based on bortezomib’s ability to downregulate HIF-1α in 
addition to proteasome inhibition. While the sample size 
was limited and few patients received paired biopsies, 
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decreases in HIF-1α expression were observed in four 
or the five patients with paired biopsies, including two 
patients who experienced a decrease in tumor size 
(although not reaching PR). Future studies in larger 
numbers of patients would be needed to explore the 
relevance of HIF-1α expression as a potential predictive 
marker. Of note, mTOR inhibitor temsirolimus has also 
demonstrated evidence of HIF-1α inhibition, and a clinical 
trial combining temsirolimus with bevacizumab and 
liposomal doxorubicin demonstrated extensive anti-tumor 
activity in multiple tumor types [44].
Similar to previously published observations [45], 
no association between plasma VEGF or VEGFR2 
changes was associated with response or duration of 
treatment. The small numbers of patients precludes 
robust calculations. New biomarkers need to be 
investigated for association with response to anti-
angiogenic activity.
Consistent with the results of VEGF SNP analysis 
in the ECOG 2100 Phase III breast cancer trial [35], 
VEGF-2578 AA correlated with better overall survival 
compared to the AC and CC genotypes. However, the 
other significant associations identified in that study 
(VEGF-1154A with superior overall survival; VEGF-
634 CC and VEGF-1498 TT associated with less grade 
3/4 hypertension) were not replicated in our clinical trial, 
possibly because of the small sample size or because of 
the heterogeneity of our patient population.
Dynamic contrast-enhanced magnetic resonance 
imaging (DCE-MRI) performed at high temporal 
resolution following the administration of a gadolinium 
(Gd)-chelated contrast medium is a noninvasive imaging 
technology that can be used to measure properties of 
tissue microvasculature. DCE-MRI is sensitive to changes 
in blood volume and vascular permeability that can be 
associated with tumor angiogenesis, and consequently 
DCE-MRI is a promising biomarker for characterizing 
tumor response to anti-angiogenic treatment [46-49].
In our study, preliminary assessment of Ktrans on 
serial DCE-MRI demonstrated a trend of dose-dependent 
decrease of Ktrans at 3 weeks, suggesting that greater 
inhibition of angiogenic activity was achieved with higher 
doses of the study medications. Because of the limited 
number of patients who underwent evaluation with DCE-
MRI, correlations between clinical response and change in 
DCE-MRI perfusion parameters are primarily exploratory 
in nature. Among the 14 patients evaluated, the four 
patients who received more than four cycles of treatment 
did not demonstrate a trend of greater decrease of Ktrans at 
either the 24-48 hour time point or the 3 week time point, 
compared to the remainder of the patients.
Overall, 20S proteasome activity significantly 
decreased within 1 and 4 hours after treatment (mean 
change −10.44%, p=0.007 and −18.81%, p=0.004, 
respectively), but changed inconsistently after Day 2/3. 
This trend was observed independent of dose level (dose 
Figure 3: HIF-1α expression in pre- and post-
treatment biopsies from renal cell carcinoma 
patient. Immunohistochemical staining of a 
representative biopsy shows that HIF-1α protein is 
strongly expressed in renal cell carcinoma cells (A; 
original magnification: ×100). Neoplastic cells identified 
by the arrow are also illustrated at a higher magnification 
(B; ×400). Post-treatment biopsy from the same patient 
shows that scattered neoplastic cells that represent less 
than 1% of the biopsy express very weak levels of HIF-
1α (C). The arrow identifies these cells (C), which are 
also shown at a higher magnification (D; ×400). Negative 
control MCF-7 cells lack the expression of HIF-1α (E; 
×400). Positive control MCF-7 cells treated with CoCl2 
demonstrate strong expression of HIF-1α (F; ×400).
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levels of bortezomib at 0.7-1.0mg/m2 (low) vs. 1.3mg/m2 
(high)), response (SD≥6 months/PR vs. SD<6 months/
PD), or toxicity (grade 2 or greater thrombocytopenia, 
diarrhea, nausea, vomiting, and/or neuropathy vs. none/
other). Contrary to expectations, pharmacodynamic 
inhibition of the 20S proteasome was not dose-dependent. 
Bortezomib’s ability to inhibit 20S proteasome activity 
in a dose-dependent manner is well documented in the 
original dose-escalation trials of single-agent bortezomib. 
Potential drug-drug interaction between bortezomib and 
bevacizumab may be considered as a potential cause of 
the findings.
In conclusion, the combination of bevacizumab and 
bortezomib is well-tolerated at full FDA-approved doses 
of each drug, and has demonstrated clinical activity in 
patients with heavily pre-treated, advanced malignancy. 
Preliminary assessment of pharmacodynamic biomarkers 
and DCE-MRI suggests that inhibition of angiogenic 
activity was achieved. Because partial responses were 
observed, especially among patients with renal cell 
carcinoma who had previously progressed on anti-
angiogenic treatment strategies, this treatment regimen 
merits further evaluation.
MATERIALS AND METHODS
Patients
Patient eligibility criteria included patients with 
advanced or metastatic cancer, who progressed following 
standard therapy or for whom no standard effective 
therapy is available; Eastern Cooperative Oncology Group 
(ECOG) performance status of ≤2; adequate bone marrow 
function (leukocytes ≥3,000/ml, absolute neutrophil count 
≥1,500/ml, platelet count ≥75,000/ml), liver (bilirubin 
≤2.0 mg/dL, alanine aminotransferase (ALT) ≤3x upper 
limit of normal (patients with liver metastases allowed 
bilirubin ≤3xULN, ALT ≤5xULN)), and kidney (creatinine 
≤2xULN); and were at least 4 weeks beyond other 
chemotherapy or radiotherapy (at least 1 week if palliative 
low dose radiotherapy given to the limbs, at least 6 weeks 
with nitrosourea or mitomycin-C, or at least 5 half-lives or 
4 weeks, whichever is shorter, for patients who received 
non-chemotherapeutic biologic agents) and recovered to 
Grade ≤1 toxicity. Patients with hemoptysis or clinically 
significant unexplained bleeding within 28 days of entering 
study, uncontrolled hypertension, clinically significant 
cardiovascular disease, uncontrolled intercurrent illness, 
hypersensitivity to study drug components, and pregnant/
lactating women were excluded.
Procedures
A modified 3+3 dose escalation scheme was used. 
Six patients were enrolled at each dose level. The cohort 
defined as the maximum tolerated dose (MTD) was 
permitted to be expanded by up to 10 patients to further 
evaluate toxicity and correlative data. At the MTD, up to 
an additional 10 patients with renal cell carcinomas (RCC) 
were permitted to be enrolled to further evaluate safety 
and efficacy. If a response was observed in a particular 
tumor type with the study drug or drug combination, then 
the study was permitted to be expanded to include a total 
of 14 participants with that tumor type. Up to an additional 
15 patients with biopsiable disease were permitted to 
enroll at the MTD once it was determined, for the purpose 
of exploratory analysis with additional optional correlative 
studies. All enrolled participants were considered in the 
dose-limiting toxicity (DLT) analysis. Bevacizumab was 
infused intravenously on day 1 of each 21-day cycle with 
a dose escalation range of 2.5-15mg/kg. Bortezomib was 
infused intravenously on days 1, 4, 8, and 11 of each 21-
day cycle with a dose escalation range of 0.7-1.3mg/m2. 
Bortezomib was infused only on days 1 and 8 of each 
cycle at the initial dose level. Treatment was repeated once 
every 21 days until prohibitive toxicity or intercurrent 
illness, tumor progression, or patient withdrawal.
Toxicities were graded using the Common 
Terminology Criteria for Adverse Events (version 3.0). 
Tumor response was assessed with Response Evaluation 
Criteria in Solid Tumors (RECIST) 1.0 and World Health 
Organization (WHO) criteria. Baseline radiological 
assessment was done within 28 days before starting 
treatment. Restaging evaluations were performed every 2 
cycles (6 weeks).
Correlatives
Dynamic contrast-enhanced magnetic resonance 
imaging (DCE-MRI)
Optional dynamic contrast-enhanced magnetic 
resonance imaging (DCE-MRI) was performed on 
consenting patients at the following time points: 
1. baseline (within one week before day 1 treatment), 
2. acute phase (24 - 48 hours after first infusion of 
bevacizumab and bortezomib), 3. chronic phase (at 
end of cycle 1). All MR data were acquired on a 1.5T 
Excite HD scanner (GE Healthcare, Waukesha, WI) 
with CRM gradient system. DCE-MRI was performed 
at high temporal resolution (<10s per imaging volume). 
Sequential magnetic resonance images were obtained 
before, during, and following the injection of gadolinium 
(Gd)-chelated contrast medium. Following the acquisition 
of localizer images, T1 mapping data were obtained 
using a multiple flip angle fast spoiled gradient recalled 
echo FSPGR sequence in a plane that included the target 
lesion(s) as well as a reference vessel. Following the T1 
mapping acquisition, the DCE-MRI scans were obtained 
during slow steady breathing using the same pulse 
sequence and from the same acquisition volume before, 
during, and following bolus administration of 0.1mmol/
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kg gadopentetate dimeglumine (Magnevist, Bayer 
Healthcare) at 3ml/s followed by a 20ml saline flush also 
given at 3ml/s. The total DCE-MRI acquisition lasted 
about 8 minutes. All DCE-MRI data were analyzed using 
a two-compartment model to yield the pharmacokinetic 
parameters: endothelial transfer constant (Ktrans, min−1), 
extracellular extravascular space volume fraction 
(ve, unitless), and contrast agent reflux rate constant 
(kep, min−
1), using CineTool/Kinmod (GE Global Research 
Center/GE Healthcare) software developed in the IDL 
environment [50].
Plasma assessment of VEGF/VEGFR2
Optional whole blood (7 mLx2) was collected from 
consenting patients at the following time points: pre-dose 
baseline, 24-48 hours after the day 1 cycle infusion, and at 
the end of cycle 1. Plasma levels of VEGF and VEGFR2 
in duplicate samples were evaluated using enzyme-linked 
immunosorbent assay (ELISA) (human VEGF QuantiGlo 
ELISA Kit recognizing VEGF121 and VEGF165 
isoforms and human sVEGF R2/KDR Quantikine ELISA 
Kit, respectively) (R&D Systems, Minneapolis, MN) 
following the manufacturer’s instructions (lower limit of 
detection=3.30pg/mL and 4.6pg/mL, respectively).
Plasma assessment of 20S proteasome inhibition
To determine proteasome 20S inhibition, optional 
whole blood (7 mLx2) was collected and PBMCs were 
isolated from consenting patients at the following time 
points: pre-dose baseline, and then 1, 4, and 24 hours 
after the initial bortezomib infusion on day 1 of cycle 1. 
After isolation, cells were washed with PBS, placed in two 
labeled cryovials and stored at −70°C in equal volume of 
RPMI-1640 with 20% DMSO until analysis.
Proteasome 20S inhibition was determined, in duplicate 
samples, by using a validated 20S proteasome activity 
EIA kit, APT280 (Chemicon, Temecula, CA) following 
the manufacturer’s instructions (lower limit of detection 
measured with control assay was 20ng/100μl reaction).
Immunohistochemical staining to assess the 
expression of HIF-1α in tumor biopsies
Optional tumor biopsies were assessed for 
evidence of malignancy on H&E stained slides. 
Immunohistochemical staining to detect the expression 
of HIF-1α protein was performed using standard 
techniques. Briefly, formalin-fixed and paraffin-
embedded tissues were deparaffinized using alcohol 
gradient. Slides were subsequently washed in 3% H2O2 
for 15 min to block endogenous peroxidase activity. 
Antigen retrieval was performed using 1× DAKO Target 
Retrieval Solution (DAKO, Carpinteria, CA) for 20min. 
Slides were then allowed to cool down for 20min at room 
temperature and blocked for 30min using the serum-free 
block solution in the Universal LSAB+ kit (DAKO). 
Purified mouse anti-human HIF-1α monoclonal 
antibody (catalogue number: 610958, BD Biosciences, 
San Diego, CA) diluted in blocking buffer (1:100) 
was added overnight at 4°C. Sequentially, slides were 
washed 3 times for 10min and incubated with secondary 
antibody LINK and then with secondary antibody 
Streptavidin each for 30 min. Slides were developed with 
3,3´-diaminodbenzidine tetrahydrochloride substrate that 
includes horseradish peroxidase, and hematoxylin was 
used for counterstaining. MCF-7 breast cancer cells were 
either untreated or treated with CoCl2 for 4 h to induce 
the expression of HIF-1α and then used as negative 
or positive control, respectively. MCF-7 cells were 
processed in formalin to prepare paraffin embedded cell 
pellets before staining. Photomicrographs were captured 
using an Olympus DP70 camera (Olympus America, 
Melville, NY) and the QCapture Suite Plus software 
(Qimaging, Surrey, BC, Canada).
VEGF single nucleotide polymorphisms (SNPs)
DNA was extracted from peripheral blood 
mononucleocytes (PBMCs) or paraffin-embedded 
tissue sections using the QIAamp® DNA Mini and 
Blood Mini Kit or QIAamp® DNA FFPE Tissue Kit 
(Qiagen, Valencia, CA) according to standard protocols 
recommended by the manufacturer. The region of interest 
was then amplified using custom PCR primers. Sanger 
sequencing was performed on a 3730xl DNA Analyzer 
(Applied Biosystems) using BigDye™ Terminator v3 
chemistry (Applied Biosystems). Mutation analysis was 
performed using SeqScape® Software v2.5 (Applied 
Biosystems).
Statistical analysis
Analyses were descriptive and exploratory. Within-
patient comparisons were analyzed using paired t-tests and 
Wilcoxon signed rank tests. Between-patient comparisons 
were analyzed using unpaired t-tests and Mann-Whitney 
tests. Correlations were assessed using either Pearson or 
Spearman correlation analyses. Non-parametric analyses 
were chosen when data were clearly not normally 
distributed and/or had clear outliers. Analysis of VEGF 
SNPs was performed using SPSS 19 computer software 
(SPSS Chicago, IL). Many of the analyses were based on 
small numbers of patients, and care must be taken when 
interpreting non-statistically-significant results. Due to 
the exploratory nature of the analyses, no adjustment was 
made for multiple testing.
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